Home Online Features Rise Therapeutics Receives FDA IND Clearance to Initiate Clinical Testing of R-5780 in Cancer
Rise Therapeutics Receives FDA IND Clearance to Initiate Clinical Testing of R-5780 in Cancer
Hand-out
Press Releases
Rise Therapeutics  
January 13, 2025

Rise Therapeutics Receives FDA IND Clearance to Initiate Clinical Testing of R-5780 in Cancer

ROCKVILLE, Md., Jan. 13, 2025 /PRNewswire/ -- Rise Therapeutics, a biotechnology company engaged in developing novel oral Immunotherapeutics, today announced that the U.S. Food and Drug Administration (FDA) has accepted

avatar profile Olean Times Herald

Olean Times Herald

email Olean Times Herald

Local & Social